ACADIA Pharmaceuticals Quarterly Income Statement
NASDAQ: ACADHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ACADIA Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, ACADIA Pharmaceuticals generated $308.0 million in revenue, up 16.4% from the same quarter a year earlier. Net income was $31.5 million (+18.1% year over year), for a net margin of 10.2% versus a median of 10.1% in the prior 5 quarters. Gross margin was 90.8% (down from 92.2%) and operating margin 12.3%.
Diluted earnings per share came in at $0.18, up from $0.16.
Summary generated from market data by MetaCap's automated system. Methodology
ACADIA Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 307.96M | 268.06M | 283.99M | 278.63M | 264.57M | 244.32M | 259.60M | 250.40M | 241.96M | 205.83M | 231.04M | 211.70M |
| Revenue growth (YoY) | +16.40% | +9.72% | +9.39% | +11.27% | +9.34% | +18.70% | +12.36% | +18.28% | +46.44% | +73.75% | +69.27% | +61.96% |
| Cost of Revenue | 28.32M | 24.79M | 26.23M | 21.65M | 20.73M | 20.39M | 21.80M | 18.86M | 18.23M | 22.95M | 17.89M | 14.62M |
| Gross Profit | 279.64M | 243.27M | 257.76M | 256.99M | 243.83M | 223.93M | 237.80M | 231.54M | 223.73M | 182.88M | 213.15M | 197.08M |
| Operating Expenses | 241.81M | 247.89M | 240.37M | 221.23M | 211.46M | 204.63M | 84.30M | 199.90M | 193.30M | 167.67M | 178.21M | 254.85M |
| Research & Development | 81.56M | 76.87M | 84.76M | 87.83M | 77.95M | 78.27M | 100.73M | 66.61M | 76.23M | 59.68M | 66.74M | 156.96M |
| Selling, General & Admin | 160.25M | 171.02M | 155.62M | 133.40M | 133.51M | 126.37M | 130.08M | 133.29M | 117.06M | 107.99M | 111.47M | 97.89M |
| Operating Income | 37.84M | -4.62M | 17.39M | 35.76M | 32.37M | 19.29M | 153.50M | 31.64M | 30.44M | 15.21M | 34.94M | -57.78M |
| Other Income (Expense) | 647.00K | 542.00K | 596.00K | 593.00K | 594.00K | 588.00K | 575.00K | 576.00K | 386.00K | 286.00K | 0 | 1.51M |
| Pretax Income | 46.47M | 3.98M | 26.32M | 44.59M | 40.21M | 27.78M | 161.09M | 38.81M | 37.18M | 21.00M | 39.70M | -52.14M |
| Income Tax | 14.97M | 344.00K | -247.25M | -27.18M | 13.54M | 8.79M | 17.34M | 6.04M | 3.79M | 4.45M | -6.09M | 13.03M |
| Net Income | 31.50M | 3.64M | 273.57M | 71.78M | 26.67M | 18.99M | 143.74M | 32.77M | 33.39M | 16.55M | 45.80M | -65.18M |
| Net Income growth (YoY) | +18.13% | -80.84% | +90.32% | +119.07% | -20.14% | +14.69% | +213.87% | — | +2897.22% | — | — | — |
| EPS (Basic) | 0.18 | 0.02 | 1.62 | 0.43 | 0.16 | 0.11 | 0.87 | 0.20 | 0.20 | 0.10 | 0.28 | -0.40 |
| EPS (Diluted) | 0.18 | 0.02 | 1.61 | 0.42 | 0.16 | 0.11 | 0.86 | 0.20 | 0.20 | 0.10 | 0.28 | -0.40 |
| Shares Outstanding (Basic) | 171.60M | 170.52M | — | 168.84M | 167.83M | 166.81M | — | 165.97M | 165.55M | 164.80M | — | 164.23M |
| Shares Outstanding (Diluted) | 172.85M | 172.71M | — | 170.65M | 168.68M | 167.67M | — | 166.18M | 166.17M | 166.62M | — | 164.23M |
| EBITDA | 38.27M | -4.34M | 17.59M | 35.98M | 32.59M | 19.52M | 153.73M | 31.87M | 30.66M | 15.45M | 35.22M | -57.42M |
| Gross Margin | 90.81% | 90.75% | 90.77% | 92.23% | 92.16% | 91.65% | 91.60% | 92.47% | 92.47% | 88.85% | 92.26% | 93.09% |
| Operating Margin | 12.29% | -1.72% | 6.12% | 12.83% | 12.24% | 7.90% | 59.13% | 12.64% | 12.58% | 7.39% | 15.12% | -27.29% |
| Net Margin | 10.23% | 136.00% | 96.33% | 25.76% | 10.08% | 7.77% | 55.37% | 13.09% | 13.80% | 8.04% | 19.82% | -30.79% |
This table shows 12 quarterly periods of ACADIA Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ACAD's reporting calendar. What is a income statement?